In order to demonstrate the efficacy of ThrCer 6 and ThrCer 7 as iNKT‐cell agonists, we tested their effects in a B16 melanoma model, in which iNKT cells play a pivotal role in initiating a NK‐cell and IFN‐γ response against tumor cells 35. Here, IFNG is linked to melanoma.